“I am profoundly grateful to Mrs. Mazumdar-Shaw for her generosity and vision in establishing the Mazumdar-Shaw Translational Research Initiative for kidney cancer at Memorial Sloan Kettering Cancer Center (MSK). Your gift has significantly boosted our research programs and will help us expand our decades-long work of leading global clinical studies with a broad impact,” tweeted Robert Motzer, MD, medical oncologist at MSK who specializes in treating kidney cancer (Renal Cell Carcinoma). (Mazumdar-Shaw’s late husband John Shaw had Renal Cell Carcinoma.) GB, you can remove this sentence if you want to, as it might be personal for her.
” The Mazumdar-Shaw Translational Research Initiative in Kidney Cancer Research is a philanthropic initiative by @kiranshaw to support the transformation of #kidney #cancer #research and care at @MSKCancerCenter , U.S.” he added.
Executive Chairperson of Bangalore-based global biopharmaceutical company Biocon Ltd, Kiran Mazundar-Shaw, has been appointed to the Board of Trustees of the Memorial Sloan Kettering Cancer Center New York. MSK has one of the most dynamic cancer research programs, globally, operating over 120 laboratories and work toward understanding each and every type of disease better.
Mazumdar-Shaw is the first woman of Indian nationality to be appointed for this role. She is among the 52 members on the board and will serve for a term of three years w.e.f. April 14, 2021.
Last updated: December 26th, 2025
